Abstract:Our appreciation of mitochondrial disease, in the context of both genetic and phenotypic heterogeneity, has blossomed over recent years with successive epidemiological studies, accrued clinical expertise and scientific advances. Epidemiological studies have encountered numerous obstacles, most importantly the initial recognition and diagnosis of a rare and variable multisystem disorder, but also complex referral pathways, specific and evolving diagnostic techniques, impaired penetrance and heteroplasmic mtDNA mutations, and the potential for ascertainment bias in disease cohorts. These inherent difficulties have contributed to both historical over- and under-representation of specific mtDNA or nuclear DNA-related mitochondrial disease. The last three decades have seen over 250 pathogenic mtDNA mutations identified, and the evolution of whole-genome sequencing is now identifying increasing numbers of pathogenic nuclear disease genes. Only recently has it been possible to estimate the prevalence of disease due to mutations of both the nuclear and mitochondrial genomes. To date, the most detailed prevalence figures available report the number of adults suffering from all forms of mitochondrial disease to be in the region of 12.5 per 100,000 of the population. One in 4300 people (23 per 100,000) carry pathogenic mutations of either nuclear or mtDNA and either have disease or are at risk of disease in the future. The most prevalent single mutation to cause mitochondrial disease is now recognised to be due to the m.3243A>G mutation in the MT-TL1 gene with a disease estimation of 3.5 per 100,000. Childhood-onset mitochondrial disease has been predicted to range from 0.5 to 1.5 cases per 100,000, approximately one-tenth of that seen in adults. Although no true population-based prevalence studies have yet been performed using laborious whole-genome sequencing, most existing studies focus on screening for individual mutations within cohorts felt to represent either the general population or the particular disease-defined cohorts. A small number of specific mtDNA mutations have been identified as causing a proportion of disease in diabetes, deafness and optic neuropathy cohorts. Although often considered a hallmark of mitochondrial disease, the prevalence of diabetes in most forms of mitochondrial disease is no higher than 10–12% as compared with a prevalence in the general population of 4.5%. The recognised association can be mainly attributed to the prevalent m.3243A>G mutation which frequently presents with maternally inherited deafness and diabetes. Deafness is common among many mtDNA mutations, usually as part of a broader phenotype, but can be the sole manifestation in the m.1555A>G mutation, particularly following exposure to aminoglycoside antibiotics. Leber’s hereditary optic neuropathy (LHON) occurs as a result of three common mutations in 90% of affected patients, with the point prevalence of disease standing at 3.7 per 100,000.The provision and development of highly specialised services, prospective cohort studies and use of objective clinical rating scales have contributed heavily to our understanding of the mitochondrial disorders today, and are likely to be instrumental in achieving more accurate epidemiological studies in mitochondrial disease in the future.

[Analysis of complexity in Chinese meteria medica industrial chain].

Clinical and genetic analysis of combined oxidative phosphorylation defificiency-10 caused by MTO1 mutation

Success, safety, and mechanisms of failure of percutaneous coronary intervention for occlusive non-drug-eluting in-stent restenosis versus native artery total occlusion.

Mutation in MTO1 involved in tRNA modification impairs mitochondrial RNA metabolism in the yeast Saccharomyces cerevisiae.

Mto1 Worked As A Modifier in the Aminoglycosides Sensitivity of Yeast Carrying A Mitochondrial 15s Rrna C1477g Mutation

A novel compound heterozygous mutation of the MTO1 gene associated with complex oxidative phosphorylation deficiency type 10

Preoperative neck ultrasound in clinical node-negative differentiated thyroid cancer.

Mitochondrial cytochrome c oxidase deficiency.

Mutations in GTPBP3 cause a mitochondrial translation defect associated with hypertrophic cardiomyopathy, lactic acidosis, and encephalopathy

Natural disease course and genotype-phenotype correlations in Complex I deficiency caused by nuclear gene defects: what we learned from 130 cases

Ketogenic Diet Treatment of Defects in the Mitochondrial Malate Aspartate Shuttle and Pyruvate Carrier

Defects in the mitochondrial-tRNA modification enzymes MTO1 and GTPBP3 promote different metabolic reprogramming through a HIF-PPARγ-UCP2-AMPK axis

Pathogenic variants in glutamyl-tRNAGln amidotransferase subunits cause a lethal mitochondrial cardiomyopathy disorder

Biallelic variants in result in reduced assembly of the mitoribosomal small subunit with altered intrinsic and extrinsic apoptosis and a Perrault syndrome-spectrum phenotype

Skeletal Phenotypes Due to Abnormalities in Mitochondrial Protein Homeostasis and Import

Identification and Functional Characterization of Mutations Within HADHB Associated with Mitochondrial Trifunctional Protein Deficiency.

Multi-level profiling unravels mitochondrial dysfunction in myotonic dystrophy type 2

Biallelic PTPMT1 variants disrupt cardiolipin metabolism and lead to a neurodevelopmental syndrome

Decoding the mitochondria without a code: mechanistic insights into mitochondrial DNA depletion syndromes

Mutations in TOMM70 lead to multi-OXPHOS deficiencies and cause severe anemia, lactic acidosis, and developmental delay

Epidemiology of Mitochondrial Disease